Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00304382 · ClinicalTrials.gov registry record · Phase 4
Humoral Determinants of Immunity to Pneumococcal Infection
A Phase 4 study, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- Phase 4
- Development phase
- 114
- Enrollment target
NCT00304382: Completed Phase 4 study, sponsored by VA Office of Research and Development.
NCT00304382 is a Phase 4 study that has completed, run by VA Office of Research and Development. The registered enrollment target is 114 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00304382, a Phase 4 study, has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 114 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether there are differences in the level of antibody to capsular polysaccharides of S. pneumoniae or the physiological activity of such antibody after vaccinating patients who have recovered from pneumococcal pneumonia with pneumococcal polysaccharide vaccine (Pneumovax) or conjugate pneumococcal vaccine (Prevnar).
Interventions
- BIOLOGICAL Prevnar
- BIOLOGICAL Pneumovax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 114 participants |
| Start Date | 2003-01-01 |
| Est. Completion | 2012-06-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00304382
The ClinicalTrials.gov registry entry for NCT00304382 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 114 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Prevnar is the first listed.
NCT00304382 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00304382 about?
NCT00304382 is a clinical study titled "Humoral Determinants of Immunity to Pneumococcal Infection". The purpose of this study is to determine whether there are differences in the level of antibody to capsular polysaccharides of S. pneumoniae or the physiological activity of such antibody after vaccinating patients who have recovered from pneumococcal pneumonia with pneumococcal polysaccharide vacc...
What is the current status of trial NCT00304382?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 114 participants. The study started on 2003-01-01. Estimated completion is 2012-06-01.
What interventions are being tested in trial NCT00304382?
The interventions under investigation include: Prevnar (BIOLOGICAL), Pneumovax (BIOLOGICAL).
Who is sponsoring clinical trial NCT00304382?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.